Fibrocell Announces Positive Feedback from Type B End-of-Phase 2 Meeting with FDA on Phase 3 Clinical Trial Design for FCX-007

Stock Information for Fibrocell Science Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Fibrocell Science Inc.

Shareholder Investigation Alert: Halper Sadeh LLP Continues to Investigate Whether the Sale of These Companies is Fair to Shareholders - FCSC, PRTO, ARTX, ROAN
SHAREHOLDER ALERT: WeissLaw LLP Investigates Fibrocell Science, Inc.
Merger Investigation Alert: Halper Sadeh LLP Continues to Investigate Whether the Sale of These Companies is Fair to Shareholders - ROAN, UCFC, SRCI, FCSC
RARX, ROAN, and FCSC SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Buyouts
Bragar Eagel & Squire, P.C. Announces that it is Investigating the Boards of Directors of SRC Energy, Pivotal Software, MAM Software Group, and Fibrocell Science on behalf of Stockholders and Encourages Investors to Contact the Firm
Shareholder Investigation Alert: Halper Sadeh LLP Continues to Investigate Whether the Sale of These Companies is Fair to Shareholders - PRTO, FCSC, SEMG, UCFC
Lifshitz & Miller LLP Announces Investigation of Church & Dwight Co., Fibrocell Science, Inc., MacroGenics, Inc., MINDBODY, Inc., PaySign, Inc., Zebra Technologies Corporation and Zynerbia Pharmaceuticals
Shareholder Investigation Alert: Halper Sadeh LLP Continues to Investigate Whether the Sale of These Companies is Fair to Shareholders - UCFC, SEMG, ALDR, FCSC

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.